Clinical Trial

Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia

Study acronym: LCAR1901
Recruiting
View on ClinicalTrials.gov →
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of relapsed and refractory immune thrombocytopenia. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19/BCMA CAR gene vector injection
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-14.
Trial Details
NCT Number NCT06973356
Lead Sponsor Anhui Provincial Hospital
Conditions Immune Thrombocytopenia (ITP)
Enrollment 18 participants
Start Date 2025-08-16
Primary Completion 2029-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-08